Brain metastases occur in 20–30% of patients with malignant tumors. While stereotactic radiosurgery (SRS) offers an effective treatment option for limited brain metastases, managing symptomatic patients with multiple metastases remains challenging due to prolonged treatment times and potential neurological complications. The dynamic conformal arc (DCA) SRS technique using a single-isocenter multi-target (DCA-SIMT) approach facilitates efficient treatment of numerous lesions. This study evaluates survival outcomes and symptom control in patients treated with DCA-SIMT SRS for multiple brain metastases. A registry based analysis was conducted on 123 patients with 560 metastatic CNS lesions treated with DCA-SIMT SRS at the Franciszek Lukaszczyk Oncology Center, Poland, between August 2018 and September 2020. The median survival time was 7.17 months. Patients were assessed for survival, local control, and treatment-related symptoms. Statistical analyses included Cox regression and Kaplan-Meier survival analysis. The 6-month and 12-month survival rates were 57% and 29%, respectively. Local control was achieved in 93% of lesions. The total planning target volume (PTV) was a significant prognostic factor (p = 0.008), with an increase in PTV associated with decreased survival. Patients with PTV ≤ 10 cm³ had significantly longer survival (p = 0.007). Histopathological subtype also influenced outcomes, with sqamous non-small cell lung cancer associated with poorer survival (p = 0.003). Neurological symptoms stabilized or improved in 61% of patients post-treatment, despite a median global V12 of 11.6 cm³, which was not associated with increased toxicity. DCA-SIMT SRS is a viable option for symptomatic patients with multiple brain metastases, offering rapid, precise treatment with significant clinical benefits.
Purpose: Brain metastases occur in up to 30% of patients with advanced cancer and remain a major clinical challenge. While WBRT was historically the standard treatment, it provided limited survival benefit and significant neurocognitive toxicity, leading to increasing use of stereotactic radiosurgery (SRS). Recent advances with single-isocenter, multi-target (SIMT) dynamic conformal arc (DCA) techniques on modern linear accelerators have enabled efficient treatment of numerous lesions within a single session, though concerns regarding geometric accuracy persist. This study aimed to evaluate local control outcomes and influencing factors following DCA-SIMT radiosurgery in patients with multiple brain metastases. Methods: We retrospectively analyzed 195 brain metastases treated using single-isocenter, multi-target dynamic conformal arc (DCA-SIMT) stereotactic radiosurgery on a Varian TrueBeam LINAC between August 2018 and September 2020. Treatment planning was performed with Brainlab Elements MultiMets software, version 2.0 and image guidance with ExacTrac. Local control was assessed on MRI according to BM-RANO criteria, while radiation-induced contrast enhancements (RICE) were identified using multiparametric MRI. The median follow-up duration was 12 months. Statistical analyses included chi-square and ROC analyses, with p < 0.05 considered statistically significant. Results: A total of 195 brain metastases in 37 patients were analyzed. Local control at 6 months was achieved in 93% of lesions, with complete or partial response in 82%. Distance-to-isocenter (DTI), gradient index (GI), and target volume (GTV/PTV) were not associated with local control. In contrast, conformity index (CI) < 1.42 predicted better treatment response (AUC = 0.698, p = 0.0006). Margin expansion ≥ 0.5 mm was associated with improved local control (p = 0.049), while higher margins did not further improve outcomes. Prescription dose showed no significant impact. The addition of immunotherapy or targeted therapy within 4 months post-SRS significantly increased the likelihood of radiographic response (OR = 2.55, p = 0.030), with the strongest association observed in lung adenocarcinoma patients (p < 0.001). Conclusions: DCA-SIMT stereotactic radiosurgery achieves high local control in patients with multiple brain metastases. Conformity index, minimal margin expansion, and systemic therapy influenced outcomes, whereas distance-to-isocenter and dose did not. Further validation is needed to optimize margins in high-DTI scenarios.
Aim: This review summarizes the current evidence on cognitive impairment in patients with glioma, with particular emphasis on the underlying mechanisms, methods for objective assessment of cognitive deficits, and currently available therapeutic strategies. Methods: Relevant literature was identified through searches of the PubMed, Cochrane Library, and Google Scholar databases. Studies addressing the mechanisms, assessment, and management of cognitive impairment in patients with glioma published between January 2000 and February 2026 were reviewed to summarize current evidence and emerging therapeutic strategies. A structured literature search and study selection process was performed. Results: Cognitive deficits represent a heterogeneous clinical problem affecting the majority of patients diagnosed with gliomas. These impairments are multifactorial in origin, resulting both from direct infiltration of white matter by the tumor process and from the cumulative toxicity of treatment modalities, including radiotherapy, chemotherapy, corticosteroid therapy, and long-term use of antiseizure medications. Analysis of the current literature confirms that modern radiotherapy techniques (e.g., hippocampal-sparing approaches) and isocitrate dehydrogenase (IDH)-targeted therapies, such as vorasidenib, may significantly delay cognitive decline. Standardized neuropsychological batteries for the objective assessment of these disturbances remain the preferred tools recommended by the International Cognition and Cancer Task Force (ICCTF). Regarding therapeutic interventions, potential benefits have been demonstrated for supportive pharmacotherapy (including memantine), while individualized neuropsychological rehabilitation has also been shown to improve patients’ quality of life.
Background: There are currently no effective treatment options for large, inoperable, centrally located thoracic lesions with poor or suboptimal response to immunotherapy. The use of SBRT for tumors larger than 5 cm in this location is limited by toxicity. Therefore, new and innovative treatment strategies are a major unmet medical need. Adaptive radiotherapy (ART) guided by MR-Linac systems, enables real-time adjustment of the treatment plan according to daily anatomical changes and tumor response. This approach is particularly beneficial in thoracic oncology, where tumor shrinkage and respiratory motion can significantly affect dose delivery. Moreover, ART may enhance the therapeutic synergy between radiotherapy and immunotherapy. Case presentation: We report the case of a 65-year-old woman diagnosed with stage IV non-small cell lung cancer (NSCLC) of mixed squamous and adenocarcinoma histology. The patient initially presented with seizures, and an MRI revealed 10 intracranial metastases alongside a 55 mm tumor in the left lung. Following stereotactic brain radiotherapy and the initiation of nivolumab plus ipilimumab, the treatment was continued with nivolumab monotherapy due to grade 3 pulmonary toxicity. Imaging demonstrated a tumor progression limited to the lung. She was then qualified for MR-guided adaptive stereotactic radiotherapy (3 × 10 Gy), delivered at 10-day intervals. Significant tumor regression required redefinition of the GTV before fractions 2 and 3. No acute or late toxicity was observed. A 6-month follow-up PET-CT revealed marked regression in tumor size (from 79 mm to 17 mm) and metabolic activity (SUVmax reduced from 33.1 to 5.13). Comparative imaging showed less extensive post-radiation lung changes than typically observed after conventional radiotherapy. Conclusion: This case illustrates the potential of MR-guided adaptive radiotherapy to enhance treatment precision, reduce toxicity, and enable immune-radiotherapy synergy. Integration of the PULSAR concept—with spaced fractions and immunotherapy—may improve tumor response. Further clinical trials are required to confirm these benefits on larger patient populations.